The Sheffield IBS Trial
This double-blind, placebo-controlled study examines the role of probiotic administration in the prevention of C. difficile-associated diarrhoea (CDAD) in elderly patients receiving antibiotic therapy.
Results showed that Lab4 probiotics reduced the incidence of Clostridium difficile diarrhoea in these patients.
46% of patients supplemented with Lab4 probiotics were positive for Clostridium difficile toxin compared to 78% of patients in the placebo group
- The participants taking the Lab4 probiotics (Group 2) showed significant reduction in Total IBS symptoms compared to placebo (Group 1, *P<0.05).
- The reductions in days with pain and bloating were achieved with Group 2.
- Satisfaction with bowel habit and quality of life were significantly improved in Group 2 (reduction in the symptom severity scores).
- Improvement in IBS symptoms diminished quickly when the Lab4 probiotic supplementation was discontinued (week 10, 2 weeks after the intervention).